Phase I Study of Dasatinib (BMS-354825) and Imatinib in Subjects With Chronic Myeloid Leukemia in Chronic Phase

Inclusion Criteria:

males and females, 18 or older
chronic phase Ph+ or BCR-ABL positive leukemia-cml/" >CML
current complete hematologic response to imatinib
lack of major molecular response
on imatinib for at least one year
on the same imatinib dose for at least 6 months
adequate hepatic and renal function

Exclusion Criteria:

History of accelerated or blast phase CML
Serious uncontrolled medical disorder or active infection
Significant cardiovascular disease or bleeding disorder
Concurrent use of medications at risk of causing Torsades de Pointe